Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 25 of 37, showing 5 Applications out of 183 total, starting on record 121, ending on 125

# Protocol No Study Title Investigator(s) & Site(s)

121.

ECCT/22/01/03   lidERA
    A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician’s Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer   
Principal Investigator(s)
1. Mansoor Saleh
Site(s) in Kenya
1. International Cancer Institute (ICI) (Uasin Gishu county)
2. Aga Khan University Hospital (Nairobi City county)
 
View

122.

ECCT/23/03/03   Moderna 1273
    A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age   
Principal Investigator(s)
1. Prof. Walter Godfrey Jaoko Jaoko
Site(s) in Kenya
1. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county)
2. Victoria Biomedical Research Institute (Kisumu county)
3. KEMRI/USAMRD (Kericho county)
4. Kenya Medical Research Institute/USAMRU (Kisumu county)
5. KEMRI CMR-Kar Geno Research Centre (Kisumu county)
6. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county)
7. KEMRI/ CDC (Kisumu county)
8. KEMRI (Kisumu county)
9. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county)
 
View

123.

ECCT/09/03/01   REMoxTB
    A randomised placebo – controlled double blind trial comparing two treatment shortening regimens with the standard regimen (two months ethambutol,  isoniazid, rifampicin and pyrazinamide followed by four months isoniazid and rifampicin) namely 1) two months moxifloxacin, isoniazid, rifampicin and  pyrazinamide followed by two months moxifloxacin, isoniazid and rifampicin and 2) two months ethambutol, moxifloxacin, rifampicin and pyrazinamide followed by  two months moxifloxacin and rifampicin for the treatment of adults with pulmonary tuberculosis   
Principal Investigator(s)
1. Evans Inyangala Amukoye
Site(s) in Kenya
Kibera D.O Health Centre
 
View

124.

ECCT/18/07/06   Hestia 3
    A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease   
Principal Investigator(s)
1. Prof Jessie Nyokabi Githanga
2. Videlis Nduba
3. Janet N Oyieko
4. Bernards Ragama Ogutu
Site(s) in Kenya
1. Gertrude’s Children’s Hospital (Nairobi City county)
2. Chandaria Health Center Clinical Research Clinic (Nairobi City county)
3. Kenya Medical Research Institute (KEMRI) Kisumu (Kisumu county)
4. KEMRI Kombewa Clinical Research Centre (Nairobi City county)
5. Kondele Children\'s Hospital (Kisumu county)
6. Strathmore University Medical Centre (Nairobi City county)
 
View

125.

ECCT/16/07/02   A Randomized Trial of Inflienza Vaccine to Reduce Adverse Vascular Events
    A Randomized Trial of Inflienza Vaccine to Reduce Adverse Vascular Events   
Principal Investigator(s)
1. Mark Loeb
Site(s) in Kenya
The Aga Khan University Hospital
 
View